Adverum Biotechnologies, Inc. (ADVM) |
|
1.06 -0.02 (-1.85%)
|
06-26 21:34 |
|
Open: |
1.07 |
Pre. Close: |
1.08 |
|
High:
|
1.11 |
Low:
|
1.015 |
|
Volume:
|
10,642,101 |
Market Cap:
|
105(M) |
|
|
|
|
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.11 - 1.12 |
1.12 - 1.12 |
|
Low:
|
1 - 1.01 |
1.01 - 1.01 |
|
Close:
|
1.05 - 1.06 |
1.06 - 1.07 |
|
Technical analysis |
as of: 2022-06-24 4:37:49 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.29 One year: 1.51 |
| Support: |
Support1: 0.92  Support2: 0.81 |
| Resistance: |
Resistance1: 1.11 Resistance2: 1.29 |
| Pivot: |
1.02 |
| Moving Average: |
MA(5): 1.04 MA(20): 0.99
MA(100): 1.17 MA(250): 1.77 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 80.5 %D(3): 74.8 |
| RSI: |
RSI(14): 58.2 |
| 52-week: |
High: 3.66 Low: 0.79 |
| Average Vol(K): |
3-Month: 1,174 (K) 10-Days: 1,924 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ADVM ] has closed below upper band by 30.4%. Bollinger Bands are 24% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 23 Jun 2022
What is Wall Street's Target Price for Adverum Biotechnologies Inc (ADVM) Stock Thursday? - InvestorsObserver
Thu, 23 Jun 2022
Adverum Biotechnologies (NASDAQ:ADVM) Share Price Passes Below 50 Day Moving Average of $1.00 - Defense World
Thu, 09 Jun 2022
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD - GlobeNewswire
Tue, 17 May 2022
Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022 - GlobeNewswire
Thu, 12 May 2022
Adverum Biotechnologies Reports First Quarter 2022 Financial Results - GlobeNewswire
Sun, 01 May 2022
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
99 (M) |
| Shares Float |
78 (M) |
|
% Held by Insiders
|
3.6 (%) |
|
% Held by Institutions
|
70 (%) |
|
Shares Short
|
5,160 (K) |
|
Shares Short P.Month
|
4,980 (K) |
Stock Financials |
|
EPS
|
-1.58 |
|
EPS Est Next Qtl
|
-0.32 |
|
EPS Est This Year
|
-1.26 |
|
EPS Est Next Year
|
-1.31 |
|
Book Value (p.s.)
|
2.86 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-22.3 |
|
Return on Equity (ttm)
|
-44.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.83 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.52 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-114 (M) |
|
Levered Free Cash Flow
|
-84 (M) |
Stock Valuations |
|
PE Ratio
|
-0.68 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.36 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.92 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
